HomeAI · summaries
Storia in 4 fonti
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the first “Protac” medicine.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
The FDA is “willing to review” an updated submission for Capricor’s Duchenne cell therapy, its CEO said. Elsewhere, a heart drug battle spilled into court and Rigel priced the…
- ·
benzinga.com
Capricor Therapeutics Shares Surge 67.22% After Hours - Capricor Therapeutics (NASDAQ:CAPR)
Capricor Therapeutics shares surged 67.22% after hours following quarterly results and an update on the FDA review of its application.
